Hyperthermia and ablation system developer BSD Medical reported second-quarter and six-month results for fiscal 2014 (end-February 28).
Total revenue for the quarter increased 106% to $1.7 million, which the company attributed to increased sales of its MicroThermX devices. BSD reported a net loss of $1.5 million, down from $1.9 million in 2013.
For the first six months of fiscal 2014, BSD's revenues doubled, from $1.5 million for the same period in 2013 to $3 million. The company had a net loss of $3 million, compared with a net loss of $4.1 million for the same period a year ago.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
